Andrea Riccardo Filippi1, Cristina Piva2, Mario Levis2, Annalisa Chiappella3, Daniele Caracciolo4, Marilena Bellò5, Gianni Bisi6, Umberto Vitolo3, Umberto Ricardi2. 1. Department of Oncology, University of Torino, Torino, Italy. Electronic address: andreariccardo.filippi@unito.it. 2. Department of Oncology, University of Torino, Torino, Italy. 3. Hematology, Città della Salute e della Scienza, Torino, Italy. 4. Hematology, Città della Salute e della Scienza and University of Torino, Torino, Italy. 5. Nuclear Medicine, Città della Salute e della Scienza, Torino, Italy. 6. Nuclear Medicine, Città della Salute e della Scienza, Torino, Italy; Department of Medical Sciences, University of Torino, Torino, Italy.
Abstract
PURPOSE: To validate, in a monoinstitutional cohort with extended follow-up, that post-rituximab chemotherapy (R-CT) (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) is a prognostic factor allowing discrimination of primary mediastinal B-cell lymphoma (PMBCL) patients at higher risk for progression after radiation therapy. METHODS AND MATERIALS: We analyzed 51 patients, and (18)FDG-PET scans were re-examined evaluating both the Deauville 5-point scale (D5PS) score and the standardized uptake value (SUV) of residual activity, if present. These parameters were then tested by univariate analysis for a potential correlation with progression-free survival (PFS) as the primary study endpoint. RESULTS: Median follow-up time was 51 months (range, 9-153 months). After R-CT, D5PS score was 1 in 10 (19.6%), 2 in 11 (21.6%), 3 in 7 (13.8%), 4 in 17 (33.3%), and 5 in 6 patients (11.7%). Forty-three out of 51 patients (84.3%) had an SUVmax ≤5, and 8 out of 51 (15.7%) had an SUVmax ≥5. Overall, 6 patients experienced progression or relapse: 1 had a D5PS score 2 (with SUVmax ≤5), and 5 had a D5PS score 5 (and SUVmax ≥5). Patients with a D5PS score 5 showed significantly lower PFS rates versus all other scores (log-rank P<.001), as did patients with SUVmax ≥5 when compared with those with SUVmax ≤5 (log-rank P<.001). CONCLUSIONS: The present study confirmed the prognostic role of (18)FDG-PET after R-CT, with patients with a D5PS score of 5 and/or an SUVmax ≥5 being at high risk of progression/relapse after RT.
PURPOSE: To validate, in a monoinstitutional cohort with extended follow-up, that post-rituximab chemotherapy (R-CT) (18)F-fluorodeoxyglucose positron emission tomography ((18)FDG-PET) is a prognostic factor allowing discrimination of primary mediastinal B-cell lymphoma (PMBCL) patients at higher risk for progression after radiation therapy. METHODS AND MATERIALS: We analyzed 51 patients, and (18)FDG-PET scans were re-examined evaluating both the Deauville 5-point scale (D5PS) score and the standardized uptake value (SUV) of residual activity, if present. These parameters were then tested by univariate analysis for a potential correlation with progression-free survival (PFS) as the primary study endpoint. RESULTS: Median follow-up time was 51 months (range, 9-153 months). After R-CT, D5PS score was 1 in 10 (19.6%), 2 in 11 (21.6%), 3 in 7 (13.8%), 4 in 17 (33.3%), and 5 in 6 patients (11.7%). Forty-three out of 51 patients (84.3%) had an SUVmax ≤5, and 8 out of 51 (15.7%) had an SUVmax ≥5. Overall, 6 patients experienced progression or relapse: 1 had a D5PS score 2 (with SUVmax ≤5), and 5 had a D5PS score 5 (and SUVmax ≥5). Patients with a D5PS score 5 showed significantly lower PFS rates versus all other scores (log-rank P<.001), as did patients with SUVmax ≥5 when compared with those with SUVmax ≤5 (log-rank P<.001). CONCLUSIONS: The present study confirmed the prognostic role of (18)FDG-PET after R-CT, with patients with a D5PS score of 5 and/or an SUVmax ≥5 being at high risk of progression/relapse after RT.
Authors: Vitaliana DE Sanctis; Alice DI Rocco; Maria Christina Cox; Maurizio Valeriani; Francesca Perrone Congedi; Dimitri Anzellini; Maria Massaro; Gianluca Vullo; Giuseppe Facondo; Flavia DE Giacomo; Marco Alfò; Daniela Prosperi; Patrizia Pizzichini; Sabrina Pelliccia; Agostino Tafuri; Maurizio Martelli; Mattia Falchetto Osti Journal: In Vivo Date: 2020 May-Jun Impact factor: 2.155
Authors: T P Vassilakopoulos; S Papageorgiou; G A Pangalis; S Chatziioannou; M K Angelopoulou; P Panayiotidis; K Konstantopoulos; P Rondogianni Journal: Leukemia Date: 2016-06-03 Impact factor: 11.528
Authors: Chelsea C Pinnix; Andrea K Ng; Bouthaina S Dabaja; Sarah A Milgrom; Jillian R Gunther; C David Fuller; Grace L Smith; Zeinab Abou Yehia; Wei Qiao; Christine F Wogan; Mani Akhtari; Osama Mawlawi; L Jeffrey Medeiros; Hubert H Chuang; William Martin-Doyle; Philippe Armand; Ann S LaCasce; Yasuhiro Oki; Michelle Fanale; Jason Westin; Sattva Neelapu; Loretta Nastoupil Journal: Blood Adv Date: 2018-06-12